A practical reference on Cyclic heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-17 and is reviewed periodically as new material appears.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
| Property | Value | Notes |
|---|---|---|
| Solubility class | Freely soluble in water | Also soluble in DMSO and some alcohols |
| Typical storage temperature | -20 C or below | Desiccated, protected from light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
| Typical reported purity | 95 percent or higher | Reference-grade material |
| Common synonyms | PT-141 | Also called bremelanotide acetate |
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
After rail services were extended to Dover in 1844, the Western Docks were used as a terminal for the Golden Arrow and other cross-channel train services with its own railway station, Dover Marine, later renamed Dover Western Docks. At Dover Marine station an estimated 5 million troops departed for the trenches of World War I and nearly 1.5 million wounded soldiers returned. In 1920 the remains of the Unknown Warrior were landed prior to transportation to London and a ceremonial interment at Westminster Abbey. Dover Marine railway station closed in 1994, later to be redeveloped into Cruise Terminal One. The Western Docks area was also used from 1968 to the early 2000s for a cross-channel hovercraft service run by Hoverspeed. Hoverspeed also ran catamaran services until being declared bankrupt in 2005. Another catamaran service was run from 2004 until November 2008 by the single ship of SpeedFerries, SpeedOne, with up to five services daily to Boulogne-sur-Mer. The hoverport has now been demolished and redeveloped as a cargo handling facility.
=== Analogues === Analogues of DET include dimethyltryptamine (DMT), dipropyltryptamine (DPT), methylethyltryptamine (MET), methylpropyltryptamine (MPT), ethylpropyltryptamine (EPT), 4-HO-DET, 5-HO-DET, 6-HO-DET, 4-AcO-DET, ethocybin (4-PO-DET or CEY-19), 6F-DET, and 2-Me-DET.
=== Research === Jennette's research encompasses clinical research based on evaluation of data obtained from patient medical records, clinical laboratory data, and pathologic evaluation of kidney biopsy specimens; basic research based on experimental investigations using specimens from patients or animal models of kidney disease; and translational research designed to apply (translate) basic research discoveries into improved diagnosis and treatment of disease in patients. Ronald J. Falk has been a colleague in many of his research works.
Sources: en.wikipedia.org
16 April – Scientists at the Riken institute demonstrate "advanced dual-chirped optical parametric amplification", which provides a 50-fold increase in the energy of single-cycle laser pulses. This new technique may advance the development of attosecond lasers. 23 April – The world's largest 3D printer, dubbed Factory of the Future 1.0 (FoF 1.0), is presented by the University of Maine. Using thermoplastic polymers, the machine can print objects as large as 96 feet (29 m) long by 32 feet (9.8 m) wide by 18 feet (5.5 m) high, at a rate of 500 pounds (230 kg) per hour. 24 April – Demonstration of synthetic diamond created at 1 atmosphere of pressure in around 150 minutes without needing seeds. 25 April – The first meta-analysis of 665 trials of conservation action such as invasive species control measuring biodiversity is published. 26 April – mRNA-4157/V940, the first personalised melanoma vaccine based on mRNA, enters a final-stage Phase III trial. 29 April Timothy A. Coleman, with the University of Alabama in Huntsville, Richard L. Thompson with the NOAA Storm Prediction Center, and Dr. Gregory S. Forbes, a retired meteorologist from The Weather Channel publish an article to the Journal of Applied Meteorology and Climatology stating, "it is apparent that the perceived shift in tornado activity from the traditional tornado alley in the Great Plains to the eastern U.S. is indeed real". Physicists outline how a subluminal warp drive that does not require exotic negative energy may be possible.
Lead poisoning (Pb), in contrast to arsenic poisoning, is caused by industrial materials, such as leaded gasoline and lead leached from plumbing. Use of leaded gasoline has declined precipitously since the 1970s. Lead (from lead(II) azide or lead styphnate used in firearms) gradually accumulates at firearms training grounds, contaminating the local environment and exposing range employees to a risk of lead poisoning. Beryllium poisoning (Be) is attributed to the ability of Be2+ to replace Mg2+ in some enzymes. Be has been classified by one agency as a carcinogen. Cadmium poisoning (Cd) came into focus with the discovery of itai-itai disease due to cadmium-contaminated waters resulting from mining in the Toyama Prefecture starting around 1912. The term refers to the severe pains (Japanese: 痛い, romanized: itai) people with the condition felt in the spine and joints. Cd2+ is thought to accumulate in the kidneys, where it tightly binds to the sulfur in cysteine-containing proteins. Cadmium is also present as a material used in many electronic devices, thus it can leach into groundwater after being disposed of into landfills of electronic waste. Chromium poisoning (Cr) is primarily due to hexavalent chromium, Cr+6, creating as a side effect of industrial processes. While hexavalent chromium is a known human carcinogen, and it has become widespread in the environment, the impact of environmental contamination with this element are not known. Mercury poisoning (Hg) came into sharp focus with the discovery of Minamata disease, named for the Japanese city of Minamata.
== Further == Reece J, Urry L, Cain M, Wasserman S, Minorsky P, Jackson R (2011). "Chapter 4&5". In Berge S, Golden B, Triglia L (eds.). Campbell Biology. Vol. Unit 1 (9th ed.). San Francisco: Pearson Benjamin Cummings. ISBN 978-0-321-55823-7.
Sources: en.wikipedia.org
The peptide is polar and charged, and reversed-phase chromatography with acidic mobile phases resolves it well from related substances. Ultraviolet detection near 214 nm gives adequate sensitivity without derivatisation.
Aqueous solutions are subject to oxidation and hydrolysis, so concentration and pH drift can occur even under refrigeration. Solid, dry material held cold and desiccated degrades far more slowly.
Mass spectrometry separates the parent from analogues that differ by a single modification, such as an amide versus acid terminus. Retention time alone is less reliable because closely related peptides can co-elute.
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.